Virkninger af carvedilol på kardiotoksicitet hos kræftpatienter, der er underkastet antracyklinterapi (CardioTox)
En prospektiv multicenter randomiseret undersøgelse for at evaluere virkningerne af carvedilol på kardiotoksicitet hos kræftpatienter, der er underkastet antracyklinterapi
Neoplasia is the main cause of general death in the Brazilian population. In 2016, they were responsible for approximately 211,343 (16%) deaths, followed by cardiovascular diseases (12.6%). Despite the high mortality rate of neoplasia, oncological treatment have advanced substantially in recent decades improving the prognosis of patients. However, growing evidence suggest that some oncological agents may induce significant toxicity that may play a major role in the quality of life, morbidity and mortality. The cardiovascular system is often negatively affected with cancer therapy, predisposing several patients to stop appropriate treatments or to have cardiovascular events related to the cardiotoxicity. The most typical manifestation of cardiotoxicity and related consequences (heart failure) are related to the use of anthracyclines. Anthracyclines are part of the chemotherapy regimen for solid tumors and hematological neoplasms in children and adults, and are associated with an increase in life expectancy. Carvedilol is an α and β-blocker that also has antioxidant properties. Preliminary studies have shown that carvedilol and its metabolites prevent lipid peroxidation, inhibit the formation and inactivate free radicals, in addition to preventing the depletion of endogenous antioxidants, such as vitamin E. These effects would potentially prevent anthracycline injury but definitive evidence is still needed. This is a multi-center, double-blind, randomized, placebo-controlled study that aims to establish the efficacy of carvedilol for the primary prevention of left ventricular systolic dysfunction in cancer patients obtained with anthracycline chemotherapy, in different schedules and doses.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
São Paulo
-
São Paulo, São Paulo, Brasilien, 01308-050
- Hospital Sirio Libanes
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- ≥18 years of age at the time of screening
- Cancer patients that will receive chemotherapy with anthracyclines.
Exclusion Criteria:
- Inability to adequate asses left ventricular function
- Previous symptoms (dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, and pulmonary and systemic congestion) suggestive of or a previous diagnosis of heart failure.
- Previous history of any cardiomyopathy (eg.: valve disease, Chagas' disease, infiltrative cardiomyopathy)
- LVEF < 50%
- Previous history of myocardial revascularization
- Permanent tachyarrhythmia (flutter, atrial fibrillation, atrial tachycardia)
- Congenital heart disease with left ventricular function impared
- Contra-indication to the use of beta-blockers.
- Pregnant or Breast-feeding females or women of childbearing age who intend to became pregnant.
- On kidney replacement therapy
- ECOG >= 4 or Karnofsky <=30
- Advanced hepatic failure (C score Child-Pugh and MELD > 15);
- Previous use of anthracycline
- Have any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, should preclude participation in this study
- Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Intervention Group
Patients allocated to the intervention group will receive carvedilol 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily according to the patients' tolerance; The dosis increments will occur every 5 days. If after the increment the patient develops bradycardia or hypotension, the dose will be reduced to the maximum tolerated dose. Carvedilol will ideally be maintained for up to 30 days after the end of chemotherapy. |
Carvedilol will be dispensed in a staggered and progressive manner, initially from 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily or development of contraindications |
|
Placebo komparator: Control Group
Patients allocated to this group will receive placebo in a presumably staggered and progressive manner similar to the group intervention. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy. |
Patients will receive placebo in a presumed staggered and progressive manner similar to the intervention group. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Drop in ejection fraction within 12 months of starting treatment.
Tidsramme: 12 months
|
Drop in ejection fraction> 10% to values less than 50% of the left ventricle |
12 months
|
|
Cardiac events within 12 months of starting treatment.
Tidsramme: 12 months
|
Cardiac events such as death, resuscitated cardiac arrest, myocardial infarction, heart failure and cardiac arrhythmias |
12 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Drop in ejection fraction within 12 months.
Tidsramme: 12 months
|
Drop in ejection fraction greater than 10% and values less than 55% |
12 months
|
|
Reduction in myocardial strain in 12 months from the start of treatment.
Tidsramme: 12 months
|
Relative reduction of more than 15% in myocardial strain |
12 months
|
|
Diastolic dysfunction within 12 months
Tidsramme: 12 months
|
Development of diastolic dysfunction within 12 months |
12 months
|
|
Elevation of biomarkers during chemotherapy and up to 12 months of follow-up
Tidsramme: 12 months
|
Elevation of biomarkers (NT-pro BNP and troponin) during chemotherapy and up to 24 months of follow-up |
12 months
|
|
Quality of life (EuroQol-5D).
Tidsramme: 12 months
|
Quality of life measured by questionnaire in up to 12 months. |
12 months
|
|
Cardiovascular complications in 12 months.
Tidsramme: 12 months
|
Cardiovascular complications (death, resuscitated cardiac arrest, myocardial infarction, heart failure and cardiac arrhythmias) in 24 months. |
12 months
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Diagnosis of neoplasia within 12 months.
Tidsramme: 12 months
|
Diagnosis of another neoplasia |
12 months
|
|
Progression of oncological disease within 12 months.
Tidsramme: 12 months
|
Progression of oncological disease |
12 months
|
|
Tumor recurrence within 12 months.
Tidsramme: 12 months.
|
Tumor recurrence |
12 months.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Renato H D. lopes, MD, PhD, Hospital Sirio-Libanes
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hjerte-kar-sygdomme
- Sår og skader
- Patologiske processer
- Hjertesygdomme
- Kemisk inducerede lidelser
- Lægemiddelrelaterede bivirkninger og uønskede reaktioner
- Strålingsskader
- Patologiske tilstande, tegn og symptomer
- Neoplasmer
- Kardiotoksicitet
- Organiske kemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Aminer
- Indoler
- Alkoholer
- Propanolaminer
- Aminoalkoholer
- Propanoler
- Heterocykliske forbindelser, 3-ring
- Carbazoler
- Carvedilol
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- AVAP-NG 989
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .